hrp0089p1-p156 | GH & IGFs P1 | ESPE2018

The Effect of Growth Hormone Treatment in Children after Hematopoietic Stem Cell Transplantation

Hoekx CA , Bresters D , Le Cessie S , Scholte C , Oostdijk W , Hannema SE

Background: Hematopoietic stem cell transplantation (HSCT) has become more common in treating malignant and nonmalignant diseases in children. However, HSCT is associated with several late effects that can impair growth, like insufficient growth hormone (GH) secretion, hypogonadism and growth plate damage. Growth hormone treatment (GHRx) is offered but limited data are available on its effect on adult height.Objective: To evaluate the effectiveness of GH...

hrp0097p1-574 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2023

Gonadal histopathology in 17beta-HSD deficiency and 5alpha-reductase deficiency

Boogers L.S. , Brüggenwirth H.T. , van Bever Y. , Hersmus R. , Bryce J. , Ahmed S.F. , Lucas-Herald A.K. , Baronio F. , Cools M. , Ellaithi M. , Globa E. , Güran T. , Hiort O. , Holterhus P.M. , MсElreavey K. , Niedziela M. , Stancampiano M.R. , Tosun B.G. , Wolffenbuttel K.P. , Oosterhuis J.W. , Looijenga L.H.J. , Hannema S.E.

Introduction: In various forms of XY disorders/differences of sex development (DSD) the risk of germ cell cancer is increased. In the 2006 DSD consensus statement this risk was estimated to be intermediate in 17beta-HSDtype3 deficiency (HSD17B3D) and low in 5alpha-reductasetype2 deficiency (SRD5A2D) but based on very few cases. Few studies have been performed since; therefore we aimed to review gonadal pathology in an international cohort with these conditions...

hrp0086p1-p823 | Syndromes: Mechanisms and Management P1 | ESPE2016

Effects of a Stressful Environment (SE) on Height, BMI and Menarche

German Alina , Mesch Gustavo , Shmoish Michael , Hochberg Ze'ev

Background: Children’s exposure to stress predicts poor health. Poor growth and maturation are recognized indicators of poor health.Objective and hypotheses: SE correlates with height, BMI and menarche. We correlated seven indicators of SE with countries’ average adult height, BMI and menarche age.Method: Data for 57 countries of average men and women’s height, BMI and menarche age were collected from WHO report. The...

hrp0086p1-p134 | Bone & Mineral Metabolism P1 | ESPE2016

A RCT Comparing the Effect of Three Different Vitamin D Supplementation Regimens on Se 25 OH Vit D in Asymptomatic Vit D Deficient Children

Simon Anna , Pragathesh P , Priyambada Leena

Background: Vitamin D plays a significant role in musculoskeletal health and various extraskeletal functions making the prevention and treatment of this vitamin (now considered as a hormone) of utmost importance. Literature on requirement/supplementation of vitamin D in asymptomatic children is scarce and this study was an attempt to see the effect of three different doses of cholecalciferol supplementation regimens in children with asymptomatic vitamin D deficiency.<p cla...

hrp0084p2-263 | Diabetes | ESPE2015

Insulin Sensitivity in Adolescents with Gender Dysphoria During Puberty Suppressing Therapy with GnRH Agonists

Schagen Sebastian , Delemarre-van de Waal Henriette , Hannema Sabine

Background: In gender dysphoric adolescents GnRH agonists can be used to suppress pubertal development of the natal sex. The metabolic implications of the pubertal suppression have not yet been explored. Insulin sensitivity is known to be influenced by pubertal changes. During puberty a decrease in insulin sensitivity is normally observed.Objective and hypotheses: The effects of GnRH agonists on insulin sensitivity during 2 years of treatment in adolesce...

hrp0097p1-367 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2023

Changes in body composition in transgender adolescents during puberty suppression and hormone treatment

Boogers Lidewij , Reijtenbagh Sterre , Wiepjes Chantal , van Trotsenburg Paul , den Heijer Martin , Hannema Sabine

Context: Transgender adolescents can be treated with puberty suppression (PS) using GnRH agonists (GnRHa), and subsequent hormone therapy (HT). Up to this date, it has not been described at what rate body composition in transgender adolescents changes during the first years of treatment. Also, it is unknown whether Tanner stage at which treatment is initiated, might affect this treatment outcome.Methods: Transgender adol...

hrp0086p2-p384 | Gonads &amp; DSD P2 | ESPE2016

The Efficacy and Safety of Gonadotropin-Releasing Hormone Analogue Treatment to Suppress Puberty in Gender Dysphoric Adolescents

Hannema Sabine , Schagen Sebastian

Background: Puberty suppression using gonadotropin releasing hormone analogues (GnRHa) is recommended by current guidelines. Although GnRHa have long been used to treat children with precocious puberty there are few data on the outcome of this treatment in gender dysphoric adolescents.Objective and hypotheses: We aimed to evaluate the efficacy and safety of triptorelin to suppress puberty in a cohort of gender dysphoric adolescents.<p class="abstext"...

hrp0092p2-257 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology | ESPE2019

Physical Changes, Laboratory Parameters and Bone Mineral Density During Testosterone Treatment in Adolescents with Gender Dysphoria

Stoffers Iris , de Vries Martine , Hannema Sabine

Introduction: Although many adolescents with gender dysphoria (GD) are being treated with GnRH analogues (GnRHa) and gender affirming hormones there is a paucity of data on the effects and side effects of this treatment in this population. We aimed to study short-term outcome of testosterone treatment in male adolescents with GD.Methods: Sixty-two adolescents who had been treated with GnRHa, and subsequently with testost...

hrp0086p1-p357 | Gonads &amp; DSD P1 | ESPE2016

Changes in Adrenal Steroids During Puberty Suppression and Cross Sex Hormone Treatment in Gender Dysphoric Adolescents

Schagen Sebastian , Lustenhouwer Paul , Hannema Sabine

Background: Current guidelines recommend that gender dysphoric adolescents be treated with puberty suppression using gonadotropin releasing hormone analogues (GnRHa) followed by cross sex hormones. However limited data are available on the safety and side effects of this treatment. In adults changes in adrenal steroids have been observed during cross sex hormone treatment.Objective and hypotheses: We aimed to investigate the effect of GnRHa and cross sex...

hrp0089p1-p241 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology P1 | ESPE2018

The Comparisons of the Adult Height Gain and the Menarchal Age of the Girls with Central Precocious Puberty after Gonadotropin Releasing Hormone Agonist Alone and Those Treated with Combined Growth Hormone Therapy

Kim Se Young , Kim Minsub

Purpose: To investigate the outcomes of GH therapy combined with GnRH agonist for short girls who diagnosed with idiopathic CPP compared to whom treated with GnRH agonist alone.Methods: We performed retrospective reviews, among 1636 patients managed for CPP, collected data of the 166 girls with CPP treated with GnRHa for 36 months or more from January 2002 to December 2016. We divided groups of patients received GnRHa alone (Group A, n=135) or G...